Guardant Health (GH) Projected to Release Quarterly Earnings on Thursday

Guardant Health (NASDAQ:GH) is projected to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Guardant Health to announce earnings of ($0.75) per share and revenue of $350.72 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Guardant Health Stock Up 2.5%

Shares of NASDAQ:GH opened at $175.00 on Wednesday. The firm has a market cap of $23.48 billion, a P/E ratio of -50.14 and a beta of 1.67. Guardant Health has a 12-month low of $74.55 and a 12-month high of $191.05. The business has a fifty day simple moving average of $169.95 and a 200 day simple moving average of $131.33.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on GH shares. Barclays increased their price target on Guardant Health from $200.00 to $220.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Morgan Stanley lifted their price objective on Guardant Health from $185.00 to $200.00 and gave the stock an “overweight” rating in a research note on Monday, October 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a report on Thursday, October 15th. Guggenheim upped their target price on Guardant Health from $190.00 to $200.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Finally, Royal Bank Of Canada increased their target price on shares of Guardant Health from $185.00 to $200.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $191.00.

Insider Activity at Guardant Health

In related news, CEO Amirali Talasaz sold 37,500 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $169.16, for a total transaction of $6,343,500.00. Following the completion of the sale, the chief executive officer owned 37,500 shares of the company’s stock, valued at $6,343,500. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Alex Azar, II sold 826 shares of Guardant Health stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $175.00, for a total value of $144,550.00. Following the completion of the sale, the director owned 825 shares of the company’s stock, valued at approximately $144,375. The trade was a 50.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 163,060 shares of company stock worth $27,538,217 over the last quarter. 5.60% of the stock is owned by company insiders.

About Guardant Health

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.

The company’s products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient’s response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.